- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01120821
Treatment of Polycythemia Vera With Gleevec
May 14, 2010 updated by: Weill Medical College of Cornell University
A Phase II Trial of the Treatment of Polycythemia Vera With Gleevec
The purpose of this research study is to evaluate the safety and effectiveness of patients with Polycythemia Vera treated with Gleevec.
Study Overview
Detailed Description
Phlebotomy is a standard temporizing treatment for Polycythemia Vera.
Performing repeated phlebotomies may lead to iron deficiency and can contribute to a rising platelet count.
This may create additional problems, such as clots particularly in patients older than 50.
There is reason to believe that the use of Gleevec may cause a decrease in the activity of the marrow so that patients may not require as many or any phlebotomies.
Thus, spleen function may possibly improve by decreasing in size and patients' platelet counts may also improve.
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10021
- Weill Cornell Medical College
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients have diagnosis of Polycythemia Vera (PV). Patients may have newly diagnosed PV.
- Patients may have previously interferon-alfa treated PV with documented resistance, refractoriness or intolerance to interferon-alfa.
- Patients may have PV with inadequate control on hydroxyurea.
- Performance status of 0, 1, or 2
Adequate end organ function, defined as the following:
- total bilirubin <1.5 x upper limit of the normal range (ULN)
- SGOT (AST) and SGPT (ALT) < 2.5 x ULN
- creatinine < 1.5 x ULN
- ANC > 1.5 x 109/L
- Written voluntary informed consent.
Exclusion Criteria:
- Female patients who are pregnant or breast-feeding.
- Patients receiving busulfan within 6 weeks of Study Day 1.
- Patients receiving interferon-alpha within 4 weeks of Study Day 1.
- Patients receiving hydroxyurea within 2 weeks of Study Day 1.
- Patients with Grade III or IV cardiac problems as defined by the New York Heart Association Criteria.
- Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable.
- Patients previously treated with Gleevec.
- Serum erythropoietin level > or = 25 units/microliter
- Abnormal O2 saturation (by pulse oximetry) or arterial pO2 (by arterial blood gas).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Study drug
Gleevec treatment
|
400 mg once daily for 12 months
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Stabilization of hematocrit
Time Frame: Weekly for the first six week of treatment, then monthly for one year from study entry.
|
Weekly for the first six week of treatment, then monthly for one year from study entry.
|
Platelet count maintenance a therapeutic range.
Time Frame: Weekly for the first six weeks of treatment, then monthly for one year from study entry.
|
Weekly for the first six weeks of treatment, then monthly for one year from study entry.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Splenomegaly (if existent)
Time Frame: Weekly for the first six weeks of treatment, then montly for one year from study entry.
|
Weekly for the first six weeks of treatment, then montly for one year from study entry.
|
Quality of life, performance status, side effects and complications during treatment.
Time Frame: Weekly for the first six weeks of treatment, then montly for one year from study entry.
|
Weekly for the first six weeks of treatment, then montly for one year from study entry.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Richard Silver, M.D., Weill Medical College of Cornell University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2002
Primary Completion (Actual)
January 1, 2007
Study Completion (Actual)
June 1, 2007
Study Registration Dates
First Submitted
May 7, 2010
First Submitted That Met QC Criteria
May 7, 2010
First Posted (Estimate)
May 11, 2010
Study Record Updates
Last Update Posted (Estimate)
May 17, 2010
Last Update Submitted That Met QC Criteria
May 14, 2010
Last Verified
May 1, 2010
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Neoplasms by Site
- Bone Marrow Diseases
- Hematologic Diseases
- Myeloproliferative Disorders
- Bone Marrow Neoplasms
- Hematologic Neoplasms
- Polycythemia Vera
- Polycythemia
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Imatinib Mesylate
Other Study ID Numbers
- 0702-375
- CSTI571AUS41 (Other Grant/Funding Number: Novartis)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Polycythemia Vera
-
PharmaEssentia Japan K.K.RecruitingPolycythemia Vera (PV)Japan
-
Novartis PharmaceuticalsCompletedPolycythemia Vera (PV)United States
-
PharmaEssentia Japan K.K.Recruiting
-
PharmaEssentia Japan K.K.CompletedPolycythemia Vera (PV)Japan
-
Memorial Sloan Kettering Cancer CenterEli Lilly and Company; Incyte CorporationRecruitingMyelofibrosis Due to and Following Polycythemia VeraUnited States
-
Ionis Pharmaceuticals, Inc.RecruitingPhlebotomy Dependent Polycythemia VeraUnited States, Canada, Hungary, United Kingdom, Australia, Poland
-
Northwestern UniversityNational Cancer Institute (NCI); Celgene; The Leukemia and Lymphoma SocietyWithdrawnPrimary Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis PhaseUnited States
-
Novartis PharmaceuticalsTerminatedPrimary Myelofibrosis | Post-Polycythemia Vera | Post-Essential ThrombocytopeniaUnited States
-
CelgeneRecruitingPrimary Myelofibrosis | Myeloproliferative Disorders | Anemia | Myelofibrosis | Post-Polycythemia Vera MyelofibrosisFrance, Belgium, Austria, Spain, Australia, Canada, Japan, United States, Korea, Republic of, Romania, Israel, Italy, China, Czechia, Germany, Greece, Ireland, Poland, United Kingdom, Hong Kong, Hungary, Lebanon, Colombia, Argentina, Chile and more
-
CelgeneImpact Biomedicines, Inc., a wholly owned subsidiary of Celgene CorporationActive, not recruitingPrimary Myelofibrosis | Myelofibrosis | Post-Polycythemia VeraAustralia, Austria, Belgium, China, Czechia, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Ireland, United Kingdom
Clinical Trials on Gleevec
-
M.D. Anderson Cancer CenterNovartis PharmaceuticalsCompletedPolycythemia Vera | Chronic Myelomonocytic Leukemia | Hypereosinophilic Syndrome | Chronic Myeloid Leukemia | MastocytosisUnited States
-
National Cancer Institute (NCI)CompletedSclerotic Graft Versus Host Disease | Imatinib MesylateUnited States
-
M.D. Anderson Cancer CenterNovartisCompletedGastrointestinal Stromal TumorsUnited States
-
M.D. Anderson Cancer CenterNovartisCompletedAcute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Agnogenic Myeloid MetaplasiaUnited States
-
Jewish General HospitalNovartis PharmaceuticalsTerminatedChronic Lymphocytic LeukemiaCanada
-
M.D. Anderson Cancer CenterCompletedChronic Myelogenous LeukemiaUnited States
-
University of PittsburghNovartisCompleted
-
Annick DesjardinsAstraZeneca; Novartis PharmaceuticalsCompletedGlioblastoma | GliosarcomaUnited States
-
Steven E. CoutreNovartisTerminatedEosinophilia | Hypereosinophilic SyndromeUnited States
-
Indiana UniversityTerminatedPulmonary HypertensionUnited States